TauRx recently completed its latest Phase 3 clinical trial, named
LUCIDITY. In collaboration with neurologists and clinical research centres in North America and Europe, this trial was designed to confirm efficacy of our lead compound after previous results established it had concentration dependent pharmacological effect at low dose. The trial studied the effect of our drug on patients with mild cognitive impairment due to Alzheimer's, and mild to moderate Alzheimer's.
The trial used well accepted cognitive and
functional assessment scales as well as biomarker measures (MR imaging and blood based biomarkers) to assess the potential benefits seen with our drug in delaying the progression of
Alzheimer’s disease, and includes an open-label phase during which all
participants received the drug. Patients completing the full trial were eligible for continued use of the drug under an Expanded Access Program.
Additional information on the study is available via this link.
TauRx previously completed Phase 3 trials in Alzheimer's disease and in the rare neurodegenerative disorder, behavioural variant
frontotemporal dementia (bvFTD).